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Abstract
Background: The genetic basis of amyotrophic lateral sclerosis (ALS) is not entirely clear. While there are families with rare
highly penetrant mutations in Cu/Zn superoxide dismutase 1 and several other genes that cause apparent Mendelian
inheritance of the disease, most ALS occurs in families without another affected individual. However, twin studies suggest
that all ALS has a substantial genetic basis. Herein, we estimate the genetic contribution to ALS in a clinically ascertained
case series from the United States.
Methodology/Principal Findings: We used the database of the Emory ALS Center to ascertain individuals with ALS along
with their family histories to determine the concordance among parents and offspring for the disease. We found that
concordance for all parent–offspring pairs was low (,2%). With this concordance we found that ALS heritability, or the
proportion of the disease explained by genetic factors, is between 40 and 45% for all likely estimates of ALS lifetime
prevalence.
Conclusions/Significance: We found the lifetime risk of ALS is 1.1% in first-degree relatives of those with ALS.
Environmental and genetic factors appear nearly equally important for the development of ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS, also known as motor neuron
disease or Lou Gehrig’s disease) is a progressive and fatal
degenerative illness of motor neurons. The genetic basis of ALS
is not known; however, familial clustering of ALS has suggested a
genetic basis for the disease. In population-based studies, between
1.6% and 5.6% of individuals with ALS have a relative with ALS
[1,2]. Families with ALS frequently show autosomal dominant
transmission, although autosomal recessive pedigrees are also
described. Nearly 20% of individuals with familial ALS carry
mutations in the gene Cu/Zn superoxide dismutase 1 (SOD1) [3].
Mutations in other genes have also been described [4,5]. Thus it is
clear that some ALS cases have a strong genetic basis, but these
families account for fewer than 10% of all ALS cases. However,
the exact degree inherited genetic factors play in development of
ALS overall remains an open question.
Two studies have addressed this question using concordance for
ALS among twins, but the conclusions may be limited by the small
numbers of patients included and overlapping samples [6,7]. The
British motor neuron disease (MND) twin study found ALS
heritability to be between 38 and 85%, using 76 twin pairs [7]. A
more recent study included 171 twin pairs by combining the
British MND data with data from twins identified via an ALS
registry in the United Kingdom and from the National Swedish
Twin Registry [6]. This study found the heritability of ALS to be
76% (95% confidence interval, 60–86%) when individuals with
familial forms (i.e. known ALS in other non-twin family members)
of the disease were included. However, when familial cases were
excluded, the heritability of ALS dropped to 61% (95% confidence
interval, 38–78%).
Here we approached the heritability of ALS by examining the
concordance among ALS patients (probands) and their parents,
using a clinically ascertained population from a single ALS
clinical center. This approach is not traditional since we are
ascertaining offspring and examining the risk among their
parents; however, it is mathematically equivalent to the
traditional method of parent-offspring heritability studies where
the parent is the proband and allows larger numbers of probands
to be examined, enhancing the power of the analysis. Addition-
ally, unlike concordance among twins, concordance among
parents and offspring is unlikely to change with time since the
majority of parents are deceased by the time their offspring
develop ALS, given the mean age of ALS onset is approximately
60 years old [8,9,10]. Because the worldwide annual incidence is
fairly uniform at approximately 1–2.5 cases per 100,000, (with
the notable exception of a historical higher incidence in Guam
thought to be due to unique environmental influences in that
region [11]), we were able to estimate ALS heritability for all
plausible estimates of ALS prevalence. These estimates also take
into consideration the slight male predominance of ALS
[9,10,12].
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Objective
Our objective was to estimate the heritability of ALS using the
prevalence among relatives ascertained from the Emory ALS
Clinic in the United States.
Participants
Probands were ascertained from a case series database collected
by the Emory ALS Center from December 1997 to March 2011.
All individuals completed a standardized history that included
detailed questions on family history of ALS, a thorough neurologic
and neuromuscular examination, and/or electrophysiologic inves-
tigation. Family history was obtained both by a questionnaire and
verified at the initial interview by a clinician. Inclusion criteria
were the diagnosis of ALS and non-missing parental family history
data. Only the first identified family member was included when
multiple affected individuals in a family were available.
Concordance for ALS among Relatives
Participants indicated whether their parents had ALS. When
possible the affected parents were examined at the Emory ALS
Center. Alternatively, the medical records, including physician
notes and autopsy records, were obtained to establish the diagnosis
in the parents. We defined a concordant parent-offspring pair as a
proband with clinical ALS and a parent with ALS as determined
using the best available evidence.
Estimating ALS Heritability
We determined sex–specific concordance rates among all
combinations of parent–offspring pairs (i.e., father–daughter,
father–son, mother–daughter, and mother–son). To estimate
ALS heritability, we followed the methods of Falconer [13], and
assumed the existence of a normally distributed latent liability to
ALS in the general population. Liability in this model refers to all
possible environmental and genetic influences on the development
of ALS; individuals beyond a certain liability threshold develop
ALS, while those below the threshold do not. The threshold was
set using the lifetime prevalence of ALS for the general population.
For our model this is the lifetime ALS prevalence among the
parents’ generation. Since we do not know the lifetime prevalence
of ALS in the general population, i.e. among the parents’
generation, we first estimated heritability for all likely values of
ALS lifetime prevalence taken from the literature, and then came
up with point estimates from widely cited prevalence estimates of
ALS.
Statistical Analysis
Heritability was calculated for each combination of parent and
offspring genders independently. First, we used our estimate of the
lifetime prevalence of ALS for each gender to set the liability
threshold for that disease (x) and mean deviate of affected
individuals (a). The threshold and mean deviate were calculated
for each sex-specific parent-offspring pair. A parent-offspring
regression coefficient (b) (half heritability) was obtained using the
following equation [13]:
b~
xg{xr
ag
Here the subscripts g and r refer to the sex-specific prevalence
from the general population (i.e., proband’s sex) or relative (i.e.,
parent’s sex), respectively. The sampling variance of the regression
coefficient [13] is given by:
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1
a{b(a{x)
   2
g
Wgz
1
a
   2
g
Wr
W refers to the prevalence, and the subscripts g and r refer to the
sex-specific prevalence from the general population or relative,
respectively. Heritability (h
2) for parent-offspring pairs is [13]:
h2~2b
The standard error of heritability is [13]:
S:E: h2   
~2
ﬃﬃﬃﬃﬃﬃ
Vb
p
Mean heritability and standard error were calculated weighted by
the reciprocal of the sampling variance for each parent-offspring
pair.
Ethics
The Emory University Institutional Review Board approved of
the study, and all participants gave informed consent to be in the
Emory Clinical Research in Neurology Registry.
Results
From the Emory ALS research database we ascertained 1088
probands with ALS and parental data. Fourteen probands were
excluded from analysis because of lack of information about
parental medical history. The demographics of the study
population are given in table 1. The demographic characteristics
of our ALS population was similar to that reported from other case
series and population-based studies [8,9] with male predominance
of 1.45:1, and a mean age of onset of 58 years old.
Table 1. Demographics.
n=1088
Sex
Female (%) 452 (41.5)
Male (%) 636 (58.5)
Race
1
American Indian (%) 1 (0.2)
Asian (%) 6 (1.2)
Black (%) 80 (15.7)
White (%) 421 (82.9)
Mean Age of Onset (years 6 SD)
2 58612.7
First Symptoms
3
Bulbar (%) 279 (27.5)
Diaphragm or Other (%) 11 (1.1)
Lower Extremity (%) 364 (35.9)
Upper Extremity (%) 361 (35.6)
1Racial data collected was collected from 2007 and is present for 47.7% of the
cohort. Percentages based on 508 individuals with available data.
29.4% of probands had insufficient data to establish an age of onset.
36.6% of probands had insufficient data to establish where their first symptoms
began. Percentages were based on the total of 1015 individuals.
doi:10.1371/journal.pone.0027985.t001
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history of ALS. However, only 24 patients (2.2%) had an affected
parent. Interestingly, three individuals had affected siblings and no
affected parents, one had an affected child and a second-degree
relative, and the remaining 17 had second-degree relatives
affected. The parent-offspring concordance is shown by gender
for all probands in table 2. For all parent-offspring pairs, the
concordance was less than 2%. Concordance was least (0.5%, or 1
of 452 parent-offspring pairs) among fathers of affected women.
To estimate the heritability of a trait, we must know the
prevalence of the trait among relatives and the general population.
Since we do not know the prevalence of ALS in the general
population with certainty, we estimated the heritability for ALS
using a range of likely male and female ALS prevalence values. We
found that for all lifetime prevalence values less than 500 per
100,000 for men and 300 per 100,000 for women, ALS heritability
is between 27 and 73%. These results are graphically displayed in
figure 1. Next, we estimated ALS heritability for likely values of
ALS lifetime prevalence in the United States, assuming an average
lifespan of 70 years for men and 75 years for women for our
cohort’s parents. From the literature we found estimates for ALS
lifetime prevalence for men and women that ranged from 150–250
per 100,000 for men aged 70 years and 80–220 per 100,000 for
women aged 75 years [14]. Using these values we calculated ALS
heritability to be between 36 and 48%. We found a slightly higher
ALS heritability of 50.8% (95% confidence interval, 41.4–60.2%)
by calculating the lifetime prevalence from the estimated annual
incidence rate of ,2.0 per 100,000 in the United States [9,15].
These analyses lead us to conclude that genetic factors contribute
between 40 and 60% to the risk for developing ALS. To refine
these estimates we note that under a polygenic model of disease,
heritability should be equal for each pair of parent and offspring;
however, we found that the observed value of father-daughter
pairs is significantly lower than expected for any heritability above
45% (p=0.01), implying 45% is an upper bounds for ALS
heritability.
To examine the potential confounding role of ethnicity in our
cohort, we estimated the heritability among self-identified white
individuals alone. This group was chosen because it comprises the
majority (82.9%) of the individuals for whom we have ethnicity
data. Using the lifetime ALS prevalence of 200 per 100,000, we
found ALS heritability is 58.1% (95% CI: 45.0–71.2%), similar to
what we found for the entire cohort.
Discussion
We assessed the risk of ALS among parents of affected
individuals in a large case series ascertained from the Emory
ALS Center. We found that the risk for ALS among first-degree
relatives is 1.1%, which is similar to two other studies that
estimated parent-offspring risk by examining children of affected
individuals [16,17] and implies the relative risk among first-degree
relatives is 2.2–6.9, depending on the true lifetime prevalence of
ALS in the United States. Our data also suggests that inherited
factors account for roughly half of the liability for developing ALS,
assuming no shared environmental factors. Surprisingly, we found
significantly (p=0.01) fewer concordant female probands and
father pairs than expected for heritability values above 45%.
There is no simple genetic model that explains this finding (e.g.,
autosomal dominant, recessive, X-linked, or mitochondrial), and
under the polygenic model, this group should have the highest
proportion of concordant parent-offspring pairs (instead of the
lowest), because ALS is more prevalent in males than females [13].
Recall that in our experiment the probands are the offspring.
Thus, father-daughters pairs should exhibit the highest concor-
dance because the risk of ALS is lower in women, causing affected
daughters to be shifted further from the mean female liability for
ALS than affected sons are from the mean male liability. The
consequence of affected daughters having a higher liability is that
her parents are more likely to have had ALS, particularly fathers
since the risk for ALS is higher in men. While any conclusions
from these data must be tempered by the relatively small number
of affected parent-offspring pairs, these data do suggest that either
the heritability of ALS is less than or equal to 45%, or that ALS is
not a significantly polygenic disease. Indeed, there is evidence from
the literature that there may be relatively few genetic causes that
contribute to ALS considering the recent identification of the
hexamer repeat in C9ORF72 and well-described SOD1 mutations
that account for a substantial proportion of familial and sporadic
ALS cases [4,18,19]. However, we find no convincing alternative
to the polygenic model of disease based on the observed
concordance among our cohort. Other plausible explanations
are that people generally know less about the medical health
history of their father than their mother, which is suggested by the
general trend of lower father-offspring concordance for both male
and female probands observed in the data, or that our case series is
not reflective of ALS in the general population. However, we note
that our population has a similar mean age of onset and
prevalence of familial ALS as reported for other population-based
ALS studies [1,8]. In our view, the most likely explanation of the
data is simply that the heritability of ALS is between 40 and 45%.
This is best seen in figure 1, which shows ALS heritability for all
plausible values of ALS lifetime prevalence. The two prior
European studies found a higher point estimate of ALS
heritability, but our estimate of 40% is contained within their
95% confidence intervals [6,7]. The different values may simply
reflect a true difference between the relative contribution of
environmental and genetic factors, or differences in lifetime
prevalence of ALS between the study locations. In either case, our
findings suggest ALS has roughly equivalent contribution from
genetic and environmental factors.
Our study has several strengths. First, we analyzed a large
cohort of clinically ascertained cases of ALS. Family histories,
including pedigrees, were prospectively ascertained on all
Table 2. Parent-Offspring Concordance for ALS.
Father Mother
Percent Concordance Concordant/Total Percent Concordance Concordant/Total
Female Proband 0.22% 1 / 452 1.8% 8 / 452
Male Proband
1 1.1% 7 / 635 1.3% 8 / 636
1Missing paternal data on one male proband’s father; thus the totals for Male Proband–Father and Male Proband–Mother pairs are not equal.
doi:10.1371/journal.pone.0027985.t002
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thus concordance for ALS is unlikely to change with time. One
possible concern in our study is ascertainment bias of individuals
with a stronger family history, i.e. the probability of ascertaining a
proband with family history of ALS is higher than those without
family history. In this scenario, our results would likely deviate
from what we would expect under a polygenic model of disease;
however, incomplete ascertainment of families with ALS could
also lead to acceptance of a polygenic model when it should be
rejected [20,21]. In our view, referral bias (or incomplete
ascertainment of families) seems unlikely, considering the low
number of familial ALS cases (4.1%) in our cohort that is similar to
what is seen in population-based studies of ALS that found 1.6–
5.6% familial ALS [1,2]. Another potential weakness is that we do
not know the exact prevalence of ALS in the general population,
which we addressed by using a wide range of likely ALS lifetime
prevalence values among men and women.
In summary, we found ALS has a moderate genetic basis, with a
likely heritability between 40 and 45%. It is noteworthy that in our
cohort nearly half of all concordant parent-offspring pairs are due
to known SOD1 mutations, probably because patients with a
family history of ALS undergo SOD1 mutation screening. This
raises the question of how much of ALS heritability is explained
entirely by SOD1 mutations, which should be the focus of future
investigations.
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